MW Sarepta Therapeutics stock falls after DMM patient dies of liver failure
Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug Elevidys, which is used to treat Duchenne muscular dystrophy.
While liver failure is a known possible side effect of Elevidys, it had not yet been reported until now, Sarepta (SRPT) said.
"Acute liver failure leading to death represents a severity of acute liver injury notpreviously reported for Elevidys, which to date has been used to treat more than 800 patients inclinical trials or as a prescribed therapy," the company said.
Prior to Tuesday's moves, Sarepta's stock was down 16.7% so far in 2025, while Nasdaq COMP has dropped 7.8%.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 18, 2025 09:02 ET (13:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。